Prota Therapeutics
Prota Therapeutics is an Australian biotech company established in 2016, focusing on developing and commercializing oral immunotherapy treatments for food allergies, particularly peanut allergies. Their lead product, PRT120, is a Phase 3-ready treatment derived from over two decades of research led by Professor Mimi Tang at the Murdoch Children's Research Institute in Melbourne. The company is headquartered in Melbourne, Australia.
- biotech
- Biotech
Investors
Investor